Iscover: Uses, Dosage & Side Effects
An antiplatelet P2Y12 receptor inhibitor containing clopidogrel 75 mg for the prevention of atherothrombotic events including heart attack, stroke, and vascular death
Iscover (clopidogrel) is a prescription antiplatelet medication used to prevent blood clots in patients at high risk of atherothrombotic events. It belongs to the thienopyridine class of P2Y12 receptor inhibitors and works by irreversibly blocking the adenosine diphosphate (ADP) receptor on platelets, thereby inhibiting platelet aggregation. Iscover is prescribed for the secondary prevention of myocardial infarction (heart attack), ischaemic stroke, and established peripheral arterial disease, and is widely used in combination with aspirin as dual antiplatelet therapy (DAPT) following acute coronary syndromes and coronary stent placement. Available as a 75 mg film-coated tablet for once-daily oral administration, Iscover has been a cornerstone of cardiovascular prevention since clopidogrel was first approved in the late 1990s.
Quick Facts: Iscover
Key Takeaways
- Iscover (clopidogrel 75 mg) is an antiplatelet medication that irreversibly blocks the P2Y12 ADP receptor on platelets, reducing blood clot formation in arteries and preventing heart attacks, strokes, and vascular death in high-risk patients.
- It is commonly prescribed as dual antiplatelet therapy (DAPT) in combination with low-dose aspirin after acute coronary syndromes and coronary stent placement, typically for 6–12 months depending on individual risk factors.
- Clopidogrel is a prodrug requiring hepatic activation primarily by the CYP2C19 enzyme; patients who are CYP2C19 poor metabolizers may have reduced antiplatelet response and should discuss alternative therapies with their physician.
- The most significant risk is bleeding; patients should report any unusual bruising, prolonged bleeding, blood in stool or urine, or signs of intracranial haemorrhage to their doctor immediately.
- Do not discontinue Iscover without medical advice, especially after coronary stent placement, as premature cessation significantly increases the risk of stent thrombosis, which can be fatal.
What Is Iscover and What Is It Used For?
Iscover is a brand name for clopidogrel, one of the most widely prescribed antiplatelet medications in the world. Clopidogrel belongs to the thienopyridine class of drugs, which also includes ticlopidine (the first-generation agent) and prasugrel (a newer third-generation thienopyridine). These medications share a common mechanism of action: they all inhibit the P2Y12 receptor on the surface of platelets, which is one of the two major receptors for adenosine diphosphate (ADP). ADP is a key chemical messenger released by damaged blood vessel walls and activated platelets that amplifies the platelet aggregation response, making it a critical target for antiplatelet therapy.
Platelets are small, disc-shaped blood cells that play a central role in haemostasis – the process of stopping bleeding after blood vessel injury. Under normal physiological conditions, when a blood vessel is damaged, platelets adhere to the exposed subendothelial collagen, become activated, and aggregate together to form a platelet plug. This process is essential for wound healing. However, in patients with atherosclerosis – a chronic disease characterised by the build-up of fatty plaques in artery walls – this same platelet activation mechanism can become pathological. When an atherosclerotic plaque ruptures or erodes, it exposes highly thrombogenic material to the flowing blood, triggering massive platelet activation and aggregation. This can lead to the rapid formation of an arterial thrombus (blood clot) that partially or completely blocks blood flow, resulting in acute cardiovascular events such as myocardial infarction (heart attack), ischaemic stroke, or acute limb ischaemia.
Clopidogrel is a prodrug, meaning it is pharmacologically inactive in its ingested form and must undergo biotransformation in the liver to generate its active thiol metabolite. After oral absorption, approximately 85% of the absorbed clopidogrel is rapidly hydrolysed by esterases in the blood to an inactive carboxylic acid derivative. The remaining 15% undergoes a two-step oxidative process in the liver, primarily mediated by cytochrome P450 (CYP) enzymes – most importantly CYP2C19, but also CYP3A4, CYP1A2, CYP2B6, and CYP2C9. The resulting active thiol metabolite is highly unstable and cannot be measured in plasma under standard conditions. This active metabolite forms a disulphide bridge with cysteine residues on the P2Y12 receptor, causing irreversible and permanent blockade of ADP binding for the entire remaining lifespan of the platelet (approximately 7–10 days).
The clinical evidence supporting clopidogrel is extensive and derives from several landmark randomised controlled trials. The CAPRIE trial (Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events), published in The Lancet in 1996, was the pivotal study that established clopidogrel's efficacy. This trial enrolled 19,185 patients with recent myocardial infarction, recent ischaemic stroke, or established peripheral arterial disease and randomised them to receive clopidogrel 75 mg daily or aspirin 325 mg daily. The primary endpoint – the combined risk of ischaemic stroke, myocardial infarction, or vascular death – occurred in 5.32% of patients receiving clopidogrel compared with 5.83% of patients receiving aspirin per year, representing a statistically significant 8.7% relative risk reduction in favour of clopidogrel (p = 0.043).
The CURE trial (Clopidogrel in Unstable Angina to Prevent Recurrent Events), published in the New England Journal of Medicine in 2001, was the landmark study that established dual antiplatelet therapy (DAPT) with clopidogrel plus aspirin as the standard of care for acute coronary syndromes. This trial enrolled 12,562 patients with non-ST-elevation acute coronary syndromes and showed that adding clopidogrel 75 mg daily (after a 300 mg loading dose) to aspirin for 3–12 months reduced the combined risk of cardiovascular death, non-fatal myocardial infarction, or stroke by 20% compared with aspirin alone (9.3% vs. 11.4%, p < 0.001). These results fundamentally changed cardiovascular practice worldwide.
Today, Iscover (clopidogrel) is indicated for the following conditions, as approved by the European Medicines Agency (EMA) and other international regulatory authorities:
- Secondary prevention after myocardial infarction: Patients who have had a heart attack within the preceding few days to 35 days.
- Secondary prevention after ischaemic stroke: Patients who have had an ischaemic stroke within the preceding 7 days to 6 months.
- Established peripheral arterial disease: Patients with documented peripheral arterial disease.
- Acute coronary syndrome (ACS): In combination with aspirin for patients with non-ST-elevation ACS (unstable angina or non-Q-wave myocardial infarction) and ST-elevation myocardial infarction (STEMI), including patients managed medically and those undergoing percutaneous coronary intervention (PCI) with or without stent placement.
The combination of clopidogrel with aspirin (dual antiplatelet therapy or DAPT) provides complementary inhibition of two distinct platelet activation pathways: aspirin blocks the cyclooxygenase-1 (COX-1) enzyme and thromboxane A2-mediated platelet activation, while clopidogrel blocks the P2Y12 ADP receptor-mediated pathway. Together, these agents provide more comprehensive platelet inhibition than either drug alone, which is particularly important in high-risk clinical scenarios such as after coronary stent placement, where the foreign surface of the stent is highly thrombogenic until it becomes covered by new endothelial cells (endothelialisation).
What Should You Know Before Taking Iscover?
Contraindications
Iscover must not be used in patients with active pathological bleeding, such as peptic ulcer or intracranial haemorrhage. The antiplatelet effect of clopidogrel would worsen such bleeding and could lead to life-threatening complications. It is also contraindicated in patients with severe hepatic impairment, as the liver is essential for converting clopidogrel to its active metabolite. Patients with a known hypersensitivity to clopidogrel or to any of the excipients of the tablet should not take this medication. Cross-reactivity between thienopyridines (ticlopidine, clopidogrel, prasugrel) has been reported, so patients with a documented allergic reaction to any thienopyridine should inform their doctor before starting Iscover.
Certain haematological conditions also represent contraindications or require special caution. Thrombotic thrombocytopenic purpura (TTP), a rare but serious condition characterised by microangiopathic haemolytic anaemia and thrombocytopenia, has been reported in association with clopidogrel use, sometimes after only a brief exposure. This condition requires urgent medical treatment including plasma exchange, and patients who develop unexplained purpura, fever, neurological symptoms, or renal impairment while taking clopidogrel should seek immediate medical attention.
Warnings and Precautions
Bleeding is the most important risk associated with clopidogrel therapy. Patients should be informed that it may take longer than usual for bleeding to stop when they are taking Iscover, and that they should report any unusual bleeding (including prolonged bleeding from cuts, increased bruising, nosebleeds, blood in urine or stool, or coughing up blood) to their physician. Before any planned surgical procedure, the surgeon and anaesthetist should be informed that the patient is taking clopidogrel. If antiplatelet effect is temporarily not desired, Iscover should generally be discontinued at least 5 days (and ideally 7 days) before elective surgery. However, in patients with recent coronary stent placement, premature discontinuation of antiplatelet therapy significantly increases the risk of stent thrombosis, which can result in myocardial infarction and death. The decision to discontinue clopidogrel before surgery must therefore involve a careful risk-benefit assessment by the treating cardiologist and surgeon.
A critically important pharmacogenomic consideration is the role of CYP2C19 genetic polymorphisms in clopidogrel metabolism. Approximately 2–15% of the population (depending on ethnic background, with higher prevalence in Asian, African, and Polynesian populations) carry loss-of-function alleles of CYP2C19 that reduce or eliminate the enzyme's activity. These “poor metabolizers” generate less active metabolite of clopidogrel, resulting in diminished platelet inhibition and a higher rate of cardiovascular events, including stent thrombosis. The FDA has issued a boxed warning regarding this issue. CYP2C19 genotype testing is available and may be considered to guide therapy, particularly in patients undergoing PCI, where alternative P2Y12 inhibitors such as prasugrel or ticagrelor may be preferred for poor metabolizers.
Patients with renal impairment should use clopidogrel with caution, as there is limited clinical experience in this population. Although clopidogrel itself is not renally excreted, the active metabolite's pharmacodynamics may be altered in patients with severe renal disease. Similarly, patients with moderate hepatic impairment who may have bleeding diatheses should use clopidogrel with caution, although moderate hepatic impairment is not a strict contraindication.
Pregnancy and Breastfeeding
There are no adequate and well-controlled studies of clopidogrel use during pregnancy. Animal reproductive studies have not revealed direct harmful effects on fertility, pregnancy, embryonal/foetal development, parturition, or postnatal development. However, as a precaution, Iscover should not be used during pregnancy unless clearly necessary, and only if the potential benefit justifies the potential risk to the foetus. Women of childbearing potential should discuss contraceptive measures with their doctor if treatment with clopidogrel is required.
It is not known whether clopidogrel or its metabolites are excreted in human breast milk. Animal studies have shown that clopidogrel and/or its metabolites are excreted in the milk of lactating rats. A decision must be made whether to discontinue breastfeeding or to discontinue Iscover therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother. If antiplatelet therapy is essential and breastfeeding is also strongly desired, the patient should discuss the options thoroughly with her physician.
Premature discontinuation of clopidogrel, especially in patients with coronary stents, can lead to stent thrombosis – a potentially fatal event where a blood clot forms inside the stent. If you are considering stopping clopidogrel for any reason (including planned surgery, dental procedures, or side effects), always consult your cardiologist first. Your medical team will help determine the safest approach to manage your antiplatelet therapy.
How Does Iscover Interact with Other Drugs?
Drug interactions with clopidogrel are clinically important because they can either reduce the drug's antiplatelet efficacy (leading to increased thrombotic risk) or increase bleeding risk. The most significant interactions relate to clopidogrel's dependence on CYP enzymes for metabolic activation, as well as additive effects with other antithrombotic or anticoagulant agents.
Major Interactions
The interaction between clopidogrel and proton pump inhibitors (PPIs) has been one of the most extensively studied and debated drug interactions in cardiovascular medicine. Omeprazole and esomeprazole are potent inhibitors of CYP2C19, the primary enzyme responsible for converting clopidogrel to its active metabolite. Pharmacokinetic studies have demonstrated that co-administration of omeprazole with clopidogrel reduces the active metabolite's plasma concentration by approximately 45% and reduces inhibition of ADP-induced platelet aggregation by approximately 25–30%. Both the EMA and FDA have issued warnings advising against the concomitant use of clopidogrel with omeprazole or esomeprazole. If gastroprotection is needed, pantoprazole or rabeprazole are preferred alternatives as they have minimal CYP2C19 inhibitory activity.
Combining clopidogrel with oral anticoagulants (warfarin, dabigatran, rivaroxaban, apixaban, edoxaban) substantially increases the risk of haemorrhagic complications. While there are clinical situations where this combination may be necessary (e.g., patients with atrial fibrillation who also have coronary stents), such “triple therapy” should be used for the shortest possible duration and with careful monitoring. Current guidelines recommend using reduced-dose anticoagulants and lower-dose aspirin when triple therapy is unavoidable.
Minor Interactions
Selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine, sertraline, paroxetine, and citalopram may increase bleeding risk when combined with clopidogrel. SSRIs deplete serotonin stores in platelets (serotonin plays a role in platelet aggregation), and some SSRIs (particularly fluoxetine and fluvoxamine) also inhibit CYP2C19. The clinical significance of this interaction is moderate, but patients should be monitored for signs of increased bleeding.
Non-steroidal anti-inflammatory drugs (NSAIDs) increase the risk of gastrointestinal bleeding when used concomitantly with clopidogrel. In the CAPRIE trial, the incidence of gastrointestinal haemorrhage was 2.0% in clopidogrel-treated patients. Co-administration with NSAIDs is expected to increase this risk further. Patients requiring regular analgesic or anti-inflammatory treatment should consider paracetamol as an alternative or should use NSAIDs at the lowest effective dose for the shortest duration necessary.
| Interacting Drug | Interaction Type | Clinical Effect | Recommendation |
|---|---|---|---|
| Omeprazole / Esomeprazole | CYP2C19 inhibition | Reduced antiplatelet effect (~25–30%) | Avoid; use pantoprazole instead |
| Warfarin | Additive antithrombotic | Significantly increased bleeding risk | Minimise duration; monitor INR closely |
| DOACs (rivaroxaban, apixaban, etc.) | Additive antithrombotic | Increased bleeding risk | Use reduced DOAC doses in triple therapy |
| Aspirin (low-dose) | Complementary antiplatelet | Enhanced platelet inhibition + increased bleeding | Standard DAPT; use lowest aspirin dose (75–100 mg) |
| NSAIDs (ibuprofen, naproxen, etc.) | Additive GI bleeding risk | Increased gastrointestinal haemorrhage | Avoid if possible; use paracetamol |
| SSRIs (fluoxetine, sertraline, etc.) | Platelet serotonin depletion | Modestly increased bleeding risk | Monitor for bleeding; consider alternatives |
| Fluconazole / Fluvoxamine | CYP2C19 inhibition | May reduce antiplatelet effect | Avoid if possible; monitor platelet function |
Always tell your doctor, dentist, and pharmacist that you are taking Iscover (clopidogrel) before starting any new medication, undergoing any medical or dental procedure, or taking any over-the-counter medicines or supplements. This includes herbal products such as ginkgo biloba, garlic supplements, and omega-3 fatty acids, which may also affect platelet function or bleeding risk.
What Is the Correct Dosage of Iscover?
Adults
The standard maintenance dose of Iscover for adult patients is 75 mg once daily, taken orally with or without food. No dose adjustment is required based on meals, time of day, or body weight. However, the initial approach varies depending on the clinical indication:
Secondary Prevention (Post-MI, Post-Stroke, PAD)
For patients with established atherothrombotic disease (after a recent myocardial infarction, ischaemic stroke, or with documented peripheral arterial disease), the standard dose is 75 mg once daily as monotherapy or in combination with low-dose aspirin. No loading dose is required. Treatment is generally continued long-term (often indefinitely) unless contraindications develop or the treating physician decides otherwise based on clinical reassessment.
Acute Coronary Syndromes (ACS)
For non-ST-elevation ACS (unstable angina or NSTEMI): A single loading dose of 300 mg, followed by 75 mg once daily in combination with aspirin (75–100 mg daily). Treatment should be continued for at least 12 months, as the maximum benefit was observed at 12 months in the CURE trial. For patients undergoing PCI: A loading dose of 300–600 mg is recommended (600 mg provides faster onset of platelet inhibition, typically within 2 hours), followed by 75 mg daily. The higher 600 mg loading dose is preferred in patients undergoing primary PCI for STEMI.
After Coronary Stent Placement
Dual antiplatelet therapy (clopidogrel 75 mg + aspirin 75–100 mg daily) is continued for a period determined by the type of stent and individual patient risk factors. Current ESC and ACC/AHA guidelines generally recommend: 6 months minimum for drug-eluting stents (DES), which can be shortened to 1–3 months in patients at high bleeding risk, or extended beyond 12 months in patients at high ischaemic risk and low bleeding risk. The precise duration should be individualised by the treating cardiologist.
Children
Iscover is not generally recommended for use in children and adolescents under 18 years of age. The safety and efficacy of clopidogrel in paediatric patients have not been established in large clinical trials. However, clopidogrel is sometimes used off-label in specific paediatric cardiovascular conditions (such as after Fontan surgery or Kawasaki disease with coronary aneurysms), typically under specialist guidance. In such cases, doses are usually weight-based and determined by the treating paediatric cardiologist.
Elderly
No dose adjustment is required for elderly patients. In the CAPRIE trial, patients aged 75 years and older were included and demonstrated similar relative benefits to younger patients. However, elderly patients are generally at increased risk of bleeding, so careful clinical monitoring is recommended. The risk-benefit balance should be regularly reassessed, particularly in patients with multiple comorbidities, frailty, or a history of falls.
Missed Dose
If you forget to take a dose of Iscover, take it as soon as you remember, provided it is within 12 hours of your usual dosing time. If more than 12 hours have elapsed since the missed dose, skip the forgotten dose and take the next dose at your regular time the following day. Do not take a double dose to compensate for a missed one. Because clopidogrel irreversibly inhibits platelets already in circulation (and new platelets are produced at a rate of approximately 10–15% of the total platelet pool per day), missing a single dose is unlikely to result in complete loss of antiplatelet protection. However, consistent daily dosing is important for maintaining optimal therapeutic effect.
Overdose
There is limited clinical data on the effects of clopidogrel overdose. Based on the pharmacology, overdose would be expected to result in prolonged bleeding time and subsequent bleeding complications. There is no specific antidote for clopidogrel. If rapid reversal of the antiplatelet effect is required (e.g., in the setting of life-threatening haemorrhage or emergency surgery), platelet transfusion may be considered, although its effectiveness may be limited since the transfused platelets may also be inhibited by circulating active metabolite. In case of overdose, contact a poison control centre or seek emergency medical attention immediately. General supportive measures and symptomatic treatment should be provided as needed.
| Indication | Loading Dose | Maintenance Dose | Duration |
|---|---|---|---|
| Recent MI / Ischaemic Stroke / PAD | None required | 75 mg once daily | Long-term (often indefinite) |
| Non-ST-elevation ACS | 300 mg single dose | 75 mg once daily + aspirin | Up to 12 months |
| STEMI (with PCI) | 300–600 mg single dose | 75 mg once daily + aspirin | Up to 12 months |
| After Drug-Eluting Stent | Per ACS protocol | 75 mg once daily + aspirin | 6–12 months (individualised) |
| Elderly (≥75 years) | As per indication | 75 mg once daily (no adjustment) | As per indication |
What Are the Side Effects of Iscover?
As with all medications, Iscover can cause side effects, although not everyone experiences them. The most important and most common side effects are related to the drug's intended mechanism of action: by inhibiting platelet aggregation, clopidogrel increases the tendency to bleed. It is important to understand that an increased bleeding tendency is an expected pharmacological effect of any antiplatelet agent, not an idiosyncratic adverse reaction. However, the severity of bleeding can range from trivial (minor bruising) to life-threatening (intracranial haemorrhage), and patients should be aware of the warning signs that require immediate medical attention.
In the CAPRIE clinical trial, the overall safety profile of clopidogrel 75 mg was comparable to aspirin 325 mg. The incidence of all adverse events leading to permanent discontinuation was 11.8% for clopidogrel and 12.0% for aspirin. Gastrointestinal haemorrhage occurred in 2.0% of clopidogrel patients compared with 2.7% of aspirin patients. Intracranial haemorrhage occurred in 0.35% vs. 0.49%, respectively. In the CURE trial, the addition of clopidogrel to aspirin increased the rate of major bleeding from 2.7% to 3.7% (p = 0.001) over a median treatment duration of 9 months.
The following side effects have been reported with clopidogrel, organised by frequency category according to the standard MedDRA convention:
Common
- Haematoma (bruising)
- Epistaxis (nosebleeds)
- Gastrointestinal haemorrhage (bleeding from the stomach or intestines)
- Diarrhoea
- Abdominal pain
- Dyspepsia (indigestion)
Uncommon
- Thrombocytopenia (low platelet count)
- Leucopenia (low white blood cell count)
- Eosinophilia (elevated eosinophil count)
- Intracranial haemorrhage (bleeding in the brain)
- Headache, dizziness, and paraesthesia (tingling)
- Gastric ulcer, duodenal ulcer
- Gastritis, nausea, vomiting, flatulence, constipation
- Rash, pruritus (itching)
- Haematuria (blood in urine)
- Prolonged bleeding time
Rare
- Severe neutropenia (very low neutrophil count)
- Thrombotic thrombocytopenic purpura (TTP)
- Retroperitoneal haemorrhage
- Severe gastrointestinal haemorrhage with fatal outcome
- Pancreatitis
- Hepatitis, abnormal liver function tests
- Vasculitis (inflammation of blood vessels)
- Angioedema, urticaria (hives)
- Serum sickness-like reactions
- Musculoskeletal bleeding (haemarthrosis)
Not Known
- Acquired haemophilia A
- Agranulocytosis, aplastic anaemia, pancytopenia
- Drug reaction with eosinophilia and systemic symptoms (DRESS)
- Stevens-Johnson syndrome, toxic epidermal necrolysis
- Lichen planus-like dermatitis
- Insulin autoimmune syndrome (extremely rare)
- Ageusia (complete loss of taste)
- Cross-reactive drug hypersensitivity among thienopyridines
Contact your doctor or seek emergency care immediately if you experience: unexplained or prolonged bleeding from any site; black or bloody stools (signs of gastrointestinal bleeding); coughing up blood or blood-stained sputum; severe headache, confusion, vision changes, or weakness on one side of the body (possible intracranial haemorrhage); unexplained purple spots on the skin, fever, and confusion (possible TTP); or signs of a severe allergic reaction such as difficulty breathing, swelling of the face or throat, or widespread rash.
How Should You Store Iscover?
Iscover 75 mg film-coated tablets should be stored at a temperature not exceeding 30°C (86°F). The tablets should be kept in their original blister packaging until the time of use, as this protects them from moisture and light exposure, both of which can degrade the active substance over time. Do not remove tablets from the blister strip in advance or store them in weekly pill organizers for extended periods unless the organizer is tightly closed and kept in a dry environment.
As with all medications, Iscover should be kept out of the reach and sight of children. Store the medication in a safe location, preferably a locked medicine cabinet if children are present in the household. Do not use the tablets after the expiry date (marked “EXP”) printed on the blister strip and outer carton. The expiry date refers to the last day of that month.
Do not dispose of unused or expired Iscover tablets by flushing them down the toilet or throwing them in household waste. Return unused medicines to your pharmacist, who will arrange for their safe and environmentally responsible disposal through an appropriate pharmaceutical waste programme. This practice helps protect the environment and prevents accidental ingestion by children or pets.
If you notice any visible changes in the tablets, such as discolouration, crumbling, or an unusual odour, do not take them. Contact your pharmacist to determine whether the tablets are still safe to use or if a replacement is needed. Film-coated tablets should have a smooth, uniform appearance with an intact coating.
What Does Iscover Contain?
The active substance in each Iscover 75 mg film-coated tablet is clopidogrel, present as clopidogrel hydrogen sulphate (also known as clopidogrel bisulphate). The amount of clopidogrel hydrogen sulphate per tablet is calculated to deliver 75 mg of clopidogrel base, which is the pharmacologically active moiety. Clopidogrel hydrogen sulphate is a white to off-white crystalline powder with the molecular formula C16H16ClNO2S·H2SO4 and a molecular weight of 419.9 g/mol.
The tablet core contains excipients that serve various pharmaceutical functions: mannitol (diluent/filler), macrogol 6000 (binder), microcrystalline cellulose (filler/disintegrant), low-substituted hydroxypropylcellulose (disintegrant), and hydrogenated castor oil (lubricant). These excipients are standard pharmaceutical ingredients used to ensure the tablet has appropriate hardness, disintegration properties, and manufacturing characteristics.
The film coating typically contains hypromellose (hydroxypropyl methylcellulose), titanium dioxide (E171, opacifier), iron oxide red (E172, colourant), triacetin (plasticiser), and carnauba wax (polishing agent). The film coating gives the tablet its characteristic pink colour and smooth appearance, while also protecting the core from moisture and masking the taste of the active ingredient.
Patients with known allergies or intolerances to any of the excipients listed above should inform their doctor or pharmacist before taking Iscover. Although excipient allergies are uncommon, patients with specific conditions such as fructose intolerance should be aware that mannitol may cause gastrointestinal symptoms at high doses, though the amount in a single tablet is very small. The tablet does not contain lactose, gluten, or gelatin.
Frequently Asked Questions About Iscover
Iscover and Plavix both contain the same active ingredient, clopidogrel 75 mg, and work in exactly the same way. They are different brand names for the same medication, originally developed by Sanofi. Both are bioequivalent, meaning they deliver the same amount of active drug to the body and produce the same therapeutic effect. The choice between them is typically based on availability and local prescribing practices. In many countries, generic clopidogrel is also widely available at lower cost, offering the same efficacy and safety profile as both branded products.
Moderate alcohol consumption does not directly interact with clopidogrel's mechanism of action. However, heavy or chronic alcohol use can increase the risk of gastrointestinal bleeding (which is already elevated with clopidogrel use) and may impair liver function, potentially affecting clopidogrel's metabolic activation. Additionally, alcohol can increase blood pressure and may interfere with the underlying cardiovascular condition being treated. It is generally advisable to limit alcohol intake to moderate levels (no more than 1–2 standard drinks per day) while taking Iscover, and to discuss your alcohol consumption with your doctor.
The duration of Iscover treatment depends on why it was prescribed. For secondary prevention after a heart attack, stroke, or with peripheral arterial disease, treatment is often continued indefinitely (long-term). After acute coronary syndromes with or without stent placement, dual antiplatelet therapy (clopidogrel + aspirin) is typically continued for 6–12 months. Some patients with high ischaemic risk may benefit from extended treatment beyond 12 months. Never stop taking Iscover without first consulting your doctor, as premature discontinuation – especially after coronary stent placement – can significantly increase the risk of a heart attack or stent thrombosis.
Newer P2Y12 inhibitors such as ticagrelor (Brilinta/Brilique) and prasugrel (Efient) have shown superior efficacy to clopidogrel in certain clinical settings. The PLATO trial demonstrated that ticagrelor reduced cardiovascular events compared to clopidogrel in ACS patients, and the TRITON-TIMI 38 trial showed similar benefits for prasugrel in ACS patients undergoing PCI. However, both newer agents are associated with higher bleeding risk. Clopidogrel remains a widely used and well-established option, particularly for patients who cannot tolerate ticagrelor or prasugrel (e.g., due to side effects such as dyspnoea with ticagrelor), for non-ACS indications (stroke, PAD), and as a cost-effective alternative especially in resource-limited settings. The choice of P2Y12 inhibitor should be individualised by the treating physician.
Always inform your dentist that you are taking Iscover before any dental procedure. For most routine dental treatments (fillings, cleanings, simple extractions), clopidogrel does not usually need to be stopped, as local haemostatic measures (pressure, sutures, haemostatic agents) are generally sufficient to control any increased bleeding. For more extensive oral surgery, your dentist and cardiologist should jointly decide whether temporary discontinuation is appropriate and safe. If Iscover is stopped, it should typically be discontinued 5–7 days before the procedure and restarted as soon as clinically safe after the procedure. Never stop clopidogrel on your own without medical guidance.
Yes, CYP2C19 pharmacogenomic testing can identify patients who are “poor metabolizers” – individuals who carry loss-of-function variants of the CYP2C19 gene and therefore cannot efficiently convert clopidogrel to its active metabolite. These patients may have reduced antiplatelet response and a higher risk of cardiovascular events, including stent thrombosis. If testing reveals that you are a CYP2C19 poor metabolizer, your doctor may recommend an alternative P2Y12 inhibitor (such as ticagrelor or prasugrel) that does not depend on CYP2C19 for activation. Genetic testing is not mandatory for all patients but may be particularly valuable for those undergoing coronary stent placement, where adequate platelet inhibition is critical.
References
- European Medicines Agency (EMA). Clopidogrel – Summary of Product Characteristics. Last updated 2025. Available at: EMA Clopidogrel.
- U.S. Food and Drug Administration (FDA). Plavix (clopidogrel bisulfate) – Prescribing Information. Sanofi/Bristol-Myers Squibb. Revised 2024.
- CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348(9038):1329–1339. doi:10.1016/S0140-6736(96)09457-3.
- Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation (CURE). N Engl J Med. 2001;345(7):494–502. doi:10.1056/NEJMoa010746.
- Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720–3826. doi:10.1093/eurheartj/ehad191.
- Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease. Circulation. 2023;148(24):e218–e320.
- Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI. JAMA. 2010;304(16):1821–1830. doi:10.1001/jama.2010.1543.
- Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease (COGENT). N Engl J Med. 2010;363(20):1909–1917. doi:10.1056/NEJMoa1007964.
- World Health Organization (WHO). Cardiovascular diseases (CVDs). Fact Sheet. 2023. Available at: WHO CVDs.
- British National Formulary (BNF). Clopidogrel. National Institute for Health and Care Excellence (NICE). 2025.
About Our Medical Team
All content on iMedic is created and reviewed by qualified medical professionals following international evidence-based guidelines. Our editorial process ensures accuracy, currency, and clinical relevance.
Medical Content Team
Specialists in cardiology, haematology, and clinical pharmacology with extensive experience in antiplatelet therapy, acute coronary syndromes, and cardiovascular prevention.
Medical Review Board
Independent panel of board-certified physicians who verify all medical claims against current evidence and international guidelines (WHO, EMA, FDA, ESC, AHA/ACC).
Editorial Standards
All content follows the GRADE evidence framework and is based on Level 1A evidence from systematic reviews and randomized controlled trials where available.
Independence
iMedic receives no pharmaceutical company funding or sponsorship. All content is editorially independent, ensuring unbiased medical information for patients and caregivers.